anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vaccination with DC/myeloma fusion cells will be given 1-3 months following autologous transplant. Vaccination will be given at 6 weeks intervals. The monoclonal antibody CT-011 will be given 1 week following each vaccination. 3 doses of CT-011 will be given at 6 week intervals.
A vascular implant decision support uses a medical imaging system. A physics-based model of the endovascular implant is used to simulate deployment in a vessel model of a patient based on medical imaging. A porosity of the deployed implant and the simulation are used to determine a value for each of one or more hemodynamic parameters to support the decision for endovascular treatment. A machine-learned network uses patient-specific information to select the endovascular implant, placement, and/or other implant configuration used to simulate deployment and/or to predict outcome from deployment for the patient. The clinician may use the decision support to select among options for implanting and/or to confirm adequacy of a plan. Various of these approaches may be used alone or in combination.
The invention relates to the technical field of extraction of active ingredients of Chinese chestnut, and discloses a Chinese chestnut kernel extract, an extraction method thereof and application thereof in an antioxidant product. The disclosed chestnut kernel extract mainly comprises chestnut oligosaccharides and chestnut oligopeptides, wherein the chestnut oligosaccharides and the chestnut oligopeptides are extracted from chestnut kernels of short-branch chestnuts in Yanshan province. The disclosed extraction method of chestnut kernel extract comprises the following steps: extracting chestnut kernels of the Yanshan short-branch chestnut with water, and collecting oligosaccharides and oligopeptides in the water extract. The disclosed application of the chestnut kernel extract or the chestnut kernel extract extracted by the extraction method in antioxidant nourishment, health care product, skin care product and medicine. The disclosed skin care product comprises the chestnut kernel extract, wherein the concentration of the chestnut kernel extract in the skin care product is 2-10 mg/mL. The chestnut kernel extract provided by the application has remarkable antioxidant activity.
Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in low-intensity flexibility training (control group) for 30 minutes 3 times/week for 6 weeks, a time-matched session of stretching and mobility exercises. All exercise sessions will be performed on an exercise mat and conducted under investigator supervision. Participants will cease supplementation and flexibility training for a 2 week follow-up period. During this time, participants will consume 8 oz per week or consuming fish twice weekly, including one serving of oily fish.
The method that the invention discloses a kind of to extract persimmon polyphenol from persimmon, includes the following steps：A. the raw material chosen is prepared first；B. wait for that step a carries out the suction filtration of raw material again after the completion；C. after the completion of waiting for step b, the preparation of fusion liquid is carried out again after the completion；D. after the completion of waiting for step c, then the extraction of persimmon polyphenol is carried out；E. after the completion of waiting for step d, in the extraction for carrying out persimmon polyphenol, increase microwave extraction technology on the basis of ultrasonic wave auxiliary extraction technology, during micro- be extracted, to make the pressure of generation form small hole on cell membrane and cell wall, allow extracellular solvent to enter to dissolve into the cell and release intracellular organic matter, therefore yield can effectively be improved, reduce the reaction time, reduce the usage amount of solvent, the judder that can be generated using ultrasonic wave by cooperation, high acceleration, strong cavitation effect, stirring action etc., active ingredient can be accelerated to enter solvent, to improve recovery rate, shorten extraction time.
Progressive decrease of speed and guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.0 km/h.
Subjects will be screened for eligibility to participate in the study up to 28 days before dosing. Subjects will be admitted to the clinical unit on the evening prior to IMP administration (Day 1) and will fast overnight for a minimum of 8 h. Subjects will be dosed on the morning of Day 1 following a light breakfast, and will remain resident in the clinic until up to 240 h after dosing (Day 11). It is planned that subjects will be released as a group when all subjects have achieved a mass balance cumulative recovery of \>90%, or if \<1% of the dose administered has been collected in urine and faeces within 2 separate, consecutive 24 h periods. In this case, collection of all samples (blood, urine and faeces) will cease and the subjects will undergo discharge assessments. If this criterion has not been met by all subjects on Day 11, the residency period may be extended by a further 48 h maximum (up to Day 13). If the criterion is still not met by Day 13, or if additional residency is not considered appropriate or necessary, then home collections of urine and/or faeces may be requested at the discretion of the investigator for individual subjects.
The major problem with current direct delivery techniques of therapeutic reagents into solid tumors, especially of cells or large volumes of recombinant DNA reagents or drugs, has been resistance of the tissues to the influx of the fluid and/or cells, resulting in low quantities of the fluid and/or cells penetrating into and remaining in the tumor tissue to be treated.  Increased penetration and/or reduced backflow and diversion through the point of entry, so that more material is introduced into and remains in the tumor, is obtained through the use of a viscous vehicle, most preferably having a similar density to tissue, for the material to be delivered. Preferred materials include solutions or suspensions of a polymeric material which gel or solidify at the time of or shortly after injection or implantation. It has also been discovered that cells such as genetically engineered fibroblasts and keratinocytes can be cultured in the cyst fluid of encapsulated tumors. This provides a means for proliferating genetically engineered producer cells within these types of tumors, increasing the number of cells producing viral particles, which then transduce the surrounding tumor cells with the genetic material, in the preferred embodiment, a lethal gene. A number of different tumor types form "cysts", which contain fluid produced by the tumor cells, including brain tumor cells such as gliomas, and many types of breast, and lung tumors.
Lymphoma growth, progression, and dissemination require tumor cell interaction with supporting vessels and are facilitated through tumor-promoted angiogenesis, lymphangiogenesis, and/or lymphoma vessel co-option. Vessel co-option has been shown to be responsible for tumor initiation, metastasis, and resistance to anti-angiogenic treatment but is largely uncharacterized in the setting of lymphoma. We developed an in vitro model to study lymphoma-vessel interactions and found that mantle cell lymphoma (MCL) cells co-cultured on Matrigel with human umbilical vein (HUVEC) or human lymphatic (HLEC) endothelial cells migrate to and anneal with newly formed capillary-like (CLS) or lymphatic-like (LLS) structures, consistent with lymphoma-vessel co-option. To inhibit this interaction, we constructed an antibody fusion protein, αCD20-EndoP125A, linking mutant anti-angiogenic endostatin (EndoP125A) to an αCD20-IgG1-targeting antibody. αCD20-EndoP125A inhibited both CLS and LLS formation, as well as MCL migration and vessel co-option. Lymphoma vessel co-option requires cell migration, which is regulated by chemokine-chemokine receptor interactions. CXCL12 and its receptor, CXCR4, are highly expressed by both endothelial cells forming CLS and by MCL cells during vessel co-option. αCD20-EndoP125A suppressed expression of both CXCL12 and CXCR4, which were required to facilitate CLS assembly and vessel co-option. We also tested αCD20-EndoP125A effects in vivo using an aggressive murine B cell lymphoma model, 38c13-hCD20, which demonstrated rapid growth and dissemination to tumor-draining lymph nodes (TDLNs) and the spleen, lung, and brain. The pattern of lymphoma distribution and growth within the lung was consistent with vessel co-option. As predicted by our in vitro model, αCD20-EndoP125A treatment inhibited primary tumor growth, angiogenesis, and lymphangiogenesis, and markedly reduced the number of circulating tumor cells and lymphoma dissemination to TDLNs and the lungs, spleen, and brain. αCD20-EndoP125A inhibited lymphoma vessel co-option within the lung. Marked inhibition of MCL primary tumor growth and dissemination were also seen using an MCL xenograft model. The ability of αCD20-EndoP125A to inhibit angiogenesis, lymphangiogenesis, and lymphoma vessel co-option provides a novel therapeutic approach for inhibition of lymphoma progression and dissemination.
At the onset of an attack, one or two metered sprays should be administered onto or under the tongue. No more than three metered sprays are recommended within a 15-minute period. If the chest pain persists, prompt medical attention is recommended. Nitrolingual® Pumpspray may be used prophylactically five to ten minutes prior to engaging in activities which might precipitate an acute attack.  
  
Each metered spray of Nitrolingual® Pumpspray delivers 48 mg of solution containing 400 mcg of nitroglycerin after an initial priming of 5 sprays. It will remain adequately primed for 6 weeks.If the product is not used within 6 weeks it can be adequately reprimed with 1 spray. Longer storage periods without use may require up to 5 repriming sprays. There are 60 or 200 metered sprays per bottle. The total number of available doses is dependent, however, on the number of sprays per use (1 or 2 sprays), and the frequency of repriming.  
  
The transparent container can be used for continuous monitoring of the consumption. The end of the pump should be covered by the fluid level. Once fluid falls below the level of the center tube, sprays will not be adequate and the container should be replaced. As with all other sprays, there is a residual volume of fluid at the bottom of the bottle which cannot be used.   
  
During application the patient should rest, ideally in the sitting position. The container should be held vertically with the valve head uppermost and the spray orifice as close to the mouth as possible. The dose should preferably be sprayed onto the tongue by pressing the button firmly and the mouth should be closed immediately after each dose. THE SPRAY SHOULD NOT BE INHALED. The medication should not be expectorated or the mouth rinsed for 5 to 10 minutes following administration. Patients should be instructed to familiarize themselves with the position of the spray orifice, which can be identified by the finger rest on top of the valve, in order to facilitate orientation for administration at night.
The present disclosure is related to a process for the extraction and purification of feruloylglycine from natural products such as Flourensia cernua leaves using hybrid methodologies such as the combination of ultrasound and microwaves. Through this type of green methodologies, the use of polluting solvents is reduced, time is reduced and the obtaining of compounds is optimized. On the other hand, the use of resources from the semi-desert is promoted, especially those considered as waste, such as leaf, to give an added value. Through this method, feruloylglycine with bioactive potential is recovered from Flourensia cernua leaves. Dehydration, milling, extraction method, solvent removal, recovery of compounds and their characterization and identification by FTIR and HPLC/MS are presented. In addition, the estimation of its antioxidant capacity by means of the ABTS, DPPH and FRAP methods. The polyphenolic compounds obtained by this method can be used in different areas such as food, chemistry, pharmaceuticals, and cosmetics, among others.
PURPOSE:A solution for cold permanent wave having improved bad smell of thioglycollic acid, cysteine, etc., obtained by blending a solution for cold permanent wave with an emulsion of cedrene. CONSTITUTION:A solution for cold permanent wave is blended with an emulsion of cedrene to give a solution for cold permanent wave having improved bad smell. Thioglycollic acid, a salt of cysteine, etc. are mainly used as scissoring agent for cystine bond in the hair in a solution for cold permanent wave, but they are a cause of bad smell. It is found that the emulsion of cedrene eliminates the smell of thioglycollic acid, cysteine, etc. When >=80wt% cedrene based on thioglycollic acid or >=60wt% cedrene based on cycteine is added to it, its smell can be almost completely removed.
Patients Receive ruxolitinib Phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Health-related quality of life is an important outcome of cancer treatment which encompasses physical, psychological, social, and functional well-being. In addition, quality of life includes one's overall ability to become a productive member of society and achieve personal fulfillment. Treatment of pediatric cancer is a highly stressful experience which can be challenging and disruptive to the lives of children and their families. Pediatric oncology patients receiving chemotherapy often experience a decline in quality of life due to decreased activity, fatigue, and psychological distress such as depression or anxiety when compared to healthy individuals. Preliminary data suggests that there is an association between physical activity and quality of life. Exercise has been show to improve mood, increase energy levels, and reduce stress. Although more research and clinical resources have been given to the effects of exercise on quality of life among adult cancer patients, there is a lack of research in these areas among children with cancer. The investigators know little about whether children with cancer would benefit from exercise.

The investigators have added a blood sample for biomarkers. Research in adult cancer patients have shown an association between different biomarkers and sleep quality which suggests that regulation of certain biomarkers may be affected through exercise in adults. Measures of biomarkers may provide insight into potential mediators between PA, sleep quality, or fatigue levels.
Family therapy has emerged as one of the most efficacious interventions for child and adolescent behavioral and psychiatric issues and for chronic health conditions. However, widespread implementation of family therapy is often hampered by high training costs, re-training needs following staff turnover, low agency readiness to support new practices, and training strategies that lack ongoing implementation support and are prohibitively expensive. To better address the treatment needs of children and families, and to address long standing training and implementation challenges, we developed an innovative Family Therapy Training and Implementation Platform (FTTIP). FTTIP: 1) is guided by advances in implementation science, agency readiness, and knowledge of what it takes to sustain an evidence-based treatment; 2) uses adaptive training and consultation processes that provide a dynamic and data-driven procedure in which a competency is taught, measured, and the success or failure of the learning informs the next step of training in real time; 3) provides interactive practice of skills in which the trainee records interventions in response to simulation and receives personalized feedback; and 4) provides optional learning paths that allow the learner to explore additional ways to master the skills. Our Phase I study demonstrated the feasibility of FTTIP and set the stage for a fully-powered multisite Phase II Randomized Controlled Trial that will investigate whether FTTIP is "not inferior" to traditional face-to-face training on all key domains, including trainee competencies, agency readiness, and client outcomes. The Phase II study aims to: 1) Complete learning, practice and competency testing paths that provide the learner multiple learning options and to increase the dynamic nature of the platform; 2) Demonstrate that 75 FTTIP trainees show improvement in all core family therapy competencies that are not inferior to 75 providers receiving traditional in-person family therapy training as tested using pre and post training measures in a clinical trial; 3) Demonstrate that 150 families (child/parent dyad) receiving CIFFTA family therapy show adequate retention in treatment, therapeutic alliance, and significant pre-post treatment improvements on family environment and presenting problems; 4) Establish the process (e.g., initiation and delays in training new staff) and cost associated with training in each of the two conditions; 5) Demonstrate that 15 agency leaders receiving FTTIP agency readiness consultations show more pre and post change in agency readiness and knowledge than 15 leaders receiving agency engagement as usual. FTTIP's commercial application is that national, state, and local treatment services funders and providers will find FTTIP to be a highly cost effective, flexible, and engaging way to improve the quality of their evidence-based treatments (EBTs). By better preparing the nation's workforce on EBTs, and providing the support and coaching they need to reach full mastery, our FTTIP product has the potential to significantly improve the wellbeing and mental health in our nation and internationally.
The present invention relates to a process for the preparation of a compound of formula (I), wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds. The present invention relates to a process for the preparation of a compound of formula (I), wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds. Embodiments relate generally to wearable electrical and electronic hardware, computer software, wired and wireless network communications, and to wearable/mobile computing devices. More specifically, various embodiments are directed to, for example, conductive structures for a flexible substrate, a component coupled to the flexible substrate, and/or a wearable device. In one example, a wearable device includes a framework configured to be worn or attached, and a flexible substrate coupled to the framework. In some examples, the flexible substrate may have a first end and a second end, and may include one or more resilient conductive structures, and one or more rigid regions configured to receive one or more components including a sensor, or, for example, electrodes for a bioimpedance sensor.
Obesity/overweight and its complications are a growing problem in many countries. Italian Society of Bariatric and Metabolic Surgery for Obesity (Società Italiana di Chirurgia dell'Obesità e delle Malattie Metaboliche-SICOB) decided to develop the first Italian guidelines for the endoscopic bariatric treatment of obesity. The creation of SICOB Guidelines is based on an extended work made by a panel of 44 members and a coordinator. Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology has been used to decide the aims, reference population, and target health professionals. Clinical questions have been created using the PICO (patient, intervention, comparison, outcome) conceptual framework. We will perform systematic reviews, formal meta-analyses, and network meta-analyses for each PICO and critical outcomes aimed at assessing and rating the efficacy and safety of endoscopic bariatric procedures in comparison with either no interventions, lifestyle interventions, or approved anti-obesity treatments in trials with a follow-up of at least 52 weeks. For PICO on temporary endoscopic bariatric treatments, we will also consider RCT with a minimum duration of 6 months. The panel proposed 8 questions, organized into four domains: A. Indication for endoscopic bariatric surgery; B. Revisional surgery; C. Temporary gastric and duodenal-jejunal procedures; D. Endoscopic diagnosis/treatment of bariatric and metabolic surgery complications. These guidelines will apply to patients aged ≥ 14 years) with body mass index (BMI) ≥ 27 kg/m2 and requiring endoscopic bariatric surgery or endoscopic diagnostic and/or therapeutic procedures. The areas covered by the clinical questions included indications of endoscopic bariatric surgery, types of surgery, revisional surgery, and management of bariatric and metabolic surgery complications.
20 women experiencing severe pain during menstruation were randomized into two groups. The same exercise program is applied to 10 participants face-to-face, and to 10 participants via telerehabilitation. Exercises are applied for 6 weeks, 2 days a week. Visual Analog Scale (VAS) is used for pain assessment, SF-36 Short Form is used to assess quality of life, and Menstrual Attitude Scale is used to assess symptoms in the premenstrual/menstrual period. Evaluations are performed twice in total, before and after treatment. Statistical analysis will be performed with SPSS 24.0 program. If the data is parametric, paired sample t-test will be used for within-group evaluation; independent sample t-test will be used for between-group evaluation. If the data is non-parametric, Wilson test will be used for within-group evaluation and Mann Whitney U test will be used for between-group evaluation.
Provided is a chemical intermediate for preparing a disinfectant containing iodine: polyoxyethylene sorbitan monolaurate iodine complex. The polyoxyethylene sorbitan monolaurate iodine complex comprises the following components in parts: 92 to 96 parts of polyoxyethylene sorbitan monolaurate, 3 to 5 parts of iodine (I) and 1 to 3 parts of citric acid. A synthetic process comprises the following steps: adding polyoxyethylene sorbitan monolaurate into a closed stainless steel reaction kettle with temperature controller, heating to the temperature of between 50±2°C; adding citric acid, and heating to the temperature of between 95±2°C; adding iodine; after 3 hours of reaction in the reaction tank, performing uniform reaction by recycling reactants for 1 hour, then cooling to the temperature of between 30±2°C for discharging. The polyoxyethylene sorbitan monolaurate iodine complex is a form of dark violet viscous liquid with the pH value of 5-6 and iodine content of 3-5%. The finished product must be stored in dark and in a non-metallic container. The combinations of said polyoxyethylene sorbitan monolaurate iodine complex and other chemicals can make various professional disinfectant abluents, which are very effective in sterilization and disinfection of various micro-organisms, such as colibacillus, golden staphylococcus bacillus, pseudomonas aeruginosa, bacillus subtilis, hepatitis A virus and hepatitis B virus in effective concentration.